Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • U.S. Psychedelic Policy Reform
    • Worldwide Psychedelic Laws
    • Oregon Psilocybin Services Tracker
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • U.S. Psychedelic Policy Reform
    • Worldwide Psychedelic Laws
    • Oregon Psilocybin Services Tracker
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

  • Post published:August 16, 2022
  • Post category:Press Release
Read more about the article FILAMENT HEALTH ANNOUNCES PARTICIPATION IN PROJECT SOLACE

FILAMENT HEALTH ANNOUNCES PARTICIPATION IN PROJECT SOLACE

  • Post published:July 29, 2022
  • Post category:Press Release
Read more about the article FILAMENT HEALTH ANNOUNCES CLOSING OF $2,500,080 PRIVATE PLACEMENT

FILAMENT HEALTH ANNOUNCES CLOSING OF $2,500,080 PRIVATE PLACEMENT

  • Post published:July 16, 2022
  • Post category:Press Release
Read more about the article FILAMENT HEALTH ISSUED THIRD PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE

FILAMENT HEALTH ISSUED THIRD PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE

  • Post published:July 13, 2022
  • Post category:Press Release
Read more about the article FILAMENT HEALTH ANNOUNCES FIRST DOSING IN GROUNDBREAKING FDA-APPROVED PSILOCIN CLINICAL TRIAL

FILAMENT HEALTH ANNOUNCES FIRST DOSING IN GROUNDBREAKING FDA-APPROVED PSILOCIN CLINICAL TRIAL

  • Post published:July 8, 2022
  • Post category:Press Release
Read more about the article FILAMENT HEALTH ANNOUNCES SIXTH PATENT ISSUANCE

FILAMENT HEALTH ANNOUNCES SIXTH PATENT ISSUANCE

  • Post published:July 7, 2022
  • Post category:Press Release
Read more about the article FILAMENT HEALTH ANNOUNCES PRIVATE PLACEMENT OF UNITS AND CONVERTIBLE DEBENTURE UNITS OF UP TO $2,500,000

FILAMENT HEALTH ANNOUNCES PRIVATE PLACEMENT OF UNITS AND CONVERTIBLE DEBENTURE UNITS OF UP TO $2,500,000

  • Post published:July 1, 2022
  • Post category:Press Release
Read more about the article FILAMENT HEALTH ANNOUNCES PATIENT DOSING THROUGH HEALTH CANADA SPECIAL ACCESS PROGRAM

FILAMENT HEALTH ANNOUNCES PATIENT DOSING THROUGH HEALTH CANADA SPECIAL ACCESS PROGRAM

  • Post published:June 16, 2022
  • Post category:Press Release
Read more about the article Filament Health and Psyence Enter into Exclusive Licensing Agreement for Natural Psilocybin Products

Filament Health and Psyence Enter into Exclusive Licensing Agreement for Natural Psilocybin Products

  • Post published:April 19, 2022
  • Post category:Press Release
Read more about the article Filament Health Is Issued Patent By United States Patent And Trademark Office

Filament Health Is Issued Patent By United States Patent And Trademark Office

  • Post published:April 13, 2022
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More